SOURCE: Atossa Genetics Inc.

Atossa Genetics Inc.

November 07, 2014 08:00 ET

Atossa Genetics to Announce Third Quarter 2014 Financial Results and Provide a Company Update on Wednesday November 12, 2014

SEATTLE, WA--(Marketwired - Nov 7, 2014) - Atossa Genetics Inc. (NASDAQ: ATOS) announced today that it will issue financial results and corporate developments for the Third Quarter ended September 30, 2014, following the market close on Wednesday, November 12, 2014.

Management will host a conference call on Wednesday, November 12, 2014, at 4:30 pm Eastern Time to review financial results and corporate highlights. Following management's formal remarks, there will be a question and answer session.

To listen to the call by phone, interested parties within the U.S. should call 1-866-652-5200 and International callers should call 1-412-317-6060. All callers should ask for the Atossa Genetics conference call. The conference call will also be available through a live webcast at www.atossagenetics.com.

A replay of the call will be available approximately one hour after the end of the call through December 12, 2014. The replay can be accessed via Atossa's website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international) or Canada Toll Free at 855-669-9658. The replay conference ID number is 10056041.

About Atossa Genetics

Atossa Genetics Inc. is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. The laboratory services and the Company's medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For additional information, please visit www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any regulatory actions by the applicable regulatory body for where approval is currently pending for where Atossa intends to conduct business, the outcome or timing of regulatory clearances needed by Atossa to sell its products, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, recalls of products, the efficacy of Atossa's products and services, performance of distributors, estimated future expenses and cash needs, whether Atossa can launch in the United States and foreign markets the additional tests, devices and therapeutics in its pipeline in a timely and cost effective manner, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.